ClearPoint Neuro (ClearPoint Neuro) Gross Margin % : 58.93% (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is ClearPoint Neuro Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. ClearPoint Neuro's Gross Profit for the three months ended in Dec. 2023 was $4.01 Mil. ClearPoint Neuro's Revenue for the three months ended in Dec. 2023 was $6.81 Mil. Therefore, ClearPoint Neuro's Gross Margin % for the quarter that ended in Dec. 2023 was 58.93%.

Warning Sign:

ClearPoint Neuro Inc gross margin has been in long-term decline. The average rate of decline per year is -2.3%.

The historical rank and industry rank for ClearPoint Neuro's Gross Margin % or its related term are showing as below:

CLPT' s Gross Margin % Range Over the Past 10 Years
Min: 46.53 Med: 62.79 Max: 71.09
Current: 56.83

During the past 13 years, the highest Gross Margin % of ClearPoint Neuro was 71.09%. The lowest was 46.53%. And the median was 62.79%.

CLPT's Gross Margin % is ranked better than
55.53% of 796 companies
in the Medical Devices & Instruments industry
Industry Median: 53.335 vs CLPT: 56.83

ClearPoint Neuro had a gross margin of 58.93% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for ClearPoint Neuro was -2.30% per year.

ClearPoint Neuro Gross Margin % Historical Data

The historical data trend for ClearPoint Neuro's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ClearPoint Neuro Gross Margin % Chart

ClearPoint Neuro Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

64.86

71.09

68.24

65.84

56.83

ClearPoint Neuro Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Margin %	Get a 7-Day Free Trial															65.06	58.94	52.54	56.80	58.93

Competitive Comparison of ClearPoint Neuro's Gross Margin %

For the Medical Devices subindustry, ClearPoint Neuro's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ClearPoint Neuro's Gross Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ClearPoint Neuro's Gross Margin % distribution charts can be found below:

* The bar in red indicates where ClearPoint Neuro's Gross Margin % falls into.

ClearPoint Neuro Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

ClearPoint Neuro's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	13.6	/	23.955
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(23.955 - 10.341)	/	23.955
	=	56.83 %

ClearPoint Neuro's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	4	/	6.81
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(6.81 - 2.797)	/	6.81
	=	58.93 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

ClearPoint Neuro (NAS:CLPT) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

ClearPoint Neuro had a gross margin of 58.93% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

ClearPoint Neuro Gross Margin % Related Terms

Thank you for viewing the detailed overview of ClearPoint Neuro's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ClearPoint Neuro (ClearPoint Neuro) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ClearPoint Neuro Inc (NAS:CLPT) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

120 S. Sierra Avenue, Suite 100, Solana Beach, CA, USA, 92075

Website

https://www.clearpointneuro.com

ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use in the United States, is used to perform minimally invasive surgical procedures in the brain and ClearTrace is used to perform minimally invasive surgical procedures in the heart. The company's products and product candidates include ClearPoint neuro system, MRI-guided drug delivery, and Thermal therapy system.

Executives

Lynnette C Fallon	director	108 CHERRY HILL DRIVE, BEVERLY MA 01915
Linda M. Liau	director	120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Mazin Sabra	officer: Chief Operating Officer	120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Joseph Michael Burnett	director, officer: CEO and President	C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
L. Jeremy Stigall	officer: GM, Biologics & Drug Delivery	120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Danilo D'alessandro	officer: Vice President, Finance	5 MUSICK, IRVINE CA 92618
Harold A Hurwitz	officer: Chief Financial Officer
R John Fletcher	director	C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Girin Pascal E R	director	C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
B Kristine Johnson	director	366 FERNDALE RD S, WAYZATA MN 55391
Timothy T. Richards	director	ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103
Matthew B. Klein	director	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Marcio Souza	director	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Voyager Therapeutics, Inc.	10 percent owner	75 HAYDEN AVENUE, LEXINGTON MA 02421
Wendelin C Maners	officer: Vice President, Marketing	ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103